2026-05-03T10:09:56Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/274462026-04-28T00:15:57Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Raposeiras-Roubín, Sergio author Anguita, Manuel author Latini, Roberto author Domínguez-Rodríguez, Alberto author Barrabés, José A author Sánchez, Pedro L author Ottani, Filippo author Pocock, Stuart author Owen, Ruth author Cristobo, Pablo author Gómez-Talavera, Sandra author Staszewsky, Lidia author Escalera, Noemí author Fernández-Vázquez, Felipe author Bianco, Matteo author Prada-Delgado, Óscar author Pérez-García, Carlos Nicolás author Pelizzoni, Valentina author Navarro, Felipe author Pérez-Rivera, José-Ángel author Martín-Gorria, Gonzalo author Vetrano, Alfredo author Fuster, Valentín author Rosselló, Xavier author Ibáñez, Borja author 2026-04-23 Recent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may influence the effect of beta-blockers. In this prespecified subgroup analysis of the REBOOT trial, which randomized invasively managed MI patients with LVEF > 40% to beta-blockers or control, we evaluated differences in long-term effects of the intervention between STEMI (n = 4296) and NSTEMI (n = 4142). The primary endpoint was a composite of all-cause death, reinfarction, or heart failure hospitalization over a median follow-up of 3.7 years. Rev Esp Cardiol (Engl Ed). 2026 Apr 23:S1885-5857(26)00076-9. REVISTA ESPAÑOLA DE CARDIOLOGIA 42034335 https://hdl.handle.net/20.500.12105/27446 Acute coronary syndrome Beta-blockers Bloqueadores beta Ensayo clínico aleatorizado IAMCEST IAMSEST NSTEMI Randomized controlled trial STEMI Síndrome coronario agudo Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.